Soliris Reduces Risk of Relapse, Kidney Transplant Loss, Study Finds

Soliris Reduces Risk of Relapse, Kidney Transplant Loss, Study Finds

312312

Soliris Reduces Risk of Relapse, Kidney Transplant Loss, Study Finds

Soliris (eculizumab), given as a treatment or as a preventive measure, reduces disease relapse and kidney transplant loss in people with atypical hemolytic uremic syndrome (aHUS), according to a Brazilian retrospective study. Researchers emphasized the need, in low- to medium-income countries, to provide greater access to Soliris and similar therapies at a lower cost. The study, “Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort,” was published in the journal Plos…

You must be logged in to read/download the full post.